Accounts Receivable, after Allowance for Credit Loss, Current of Co-Diagnostics, Inc. from 31 Dec 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Co-Diagnostics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2018 to 30 Sep 2025.
  • Co-Diagnostics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2025 was $55,905, a 69% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Co-Diagnostics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $55,905 -$122,338 -69% 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $210,968 -$340,536 -62% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $136,391 -$298,477 -69% 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $132,570 -$171,356 -56% 31 Dec 2024 10-Q 13 Nov 2025 2025 Q3
Q3 2024 $178,243 -$628,461 -78% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $551,504 -$545,889 -50% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $434,868 -$2,267,328 -84% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $303,926 -$3,149,797 -91% 31 Dec 2023 10-Q 13 Nov 2025 2025 Q3
Q3 2023 $806,704 -$7,154,960 -90% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $1,097,393 -$11,162,616 -91% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $2,702,196 -$18,960,207 -88% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $3,453,723 -$17,385,459 -83% 31 Dec 2022 10-K 27 Mar 2025 2024 FY
Q3 2022 $7,961,664 -$6,627,935 -45% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $12,260,009 -$495,943 -3.9% 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $21,662,403 +$9,545,276 +79% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $20,839,182 +$8,702,349 +72% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $14,589,599 +$3,949,182 +37% 30 Sep 2021 10-Q 12 Nov 2021 2021 Q3
Q2 2021 $12,755,952 +$7,406,076 +138% 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $12,117,127 +$11,061,389 +1048% 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $12,136,833 +$12,005,451 +9138% 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $10,640,417 +$10,580,064 +17530% 30 Sep 2020 10-Q 16 Nov 2020 2020 Q3
Q2 2020 $5,349,876 +$5,286,891 +8394% 30 Jun 2020 10-Q/A 03 Nov 2020 2020 Q2
Q1 2020 $1,055,738 +$1,013,181 +2381% 31 Mar 2020 10-Q 14 May 2020 2020 Q1
Q4 2019 $131,382 +$117,962 +879% 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 $60,353 30 Sep 2019 10-Q 12 Nov 2019 2019 Q3
Q2 2019 $62,985 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $42,557 31 Mar 2019 10-Q 14 May 2019 2019 Q1
Q4 2018 $13,420 31 Dec 2018 10-K 30 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.